BeiGene Reaches Drug Price Reduction Deal with U.S. Government, Commits to Most-Favored-Nation Pricing for All New Drugs
nashnova research
BeiGene (BeOne Medicines) became the only Chinese drugmaker among nine companies to sign a most-favored-nation pricing deal with the Trump administration — capping its U.S. prices at the lowest paid by other developed nations, with limited near-term financial impact but a long-term ceiling now locked in.
What exactly was signed?
The White House announced on August 31 that nine pharmaceutical companies agreed to match U.S. prescription-drug prices to the lowest prices paid by other developed nations — the most-favored-nation (MFN) price.
BeiGene is the only Chinese company in the group. It will supply its PD-1 inhibitor tislelizumab (brand name: Tevimbra) at agreed prices through Medicaid, the U.S. public insurance program.
BeiGene said the deal covers roughly 8% of Tevimbra's approved-indication patient pool in the U.S. The agreement is voluntary; specific terms are confidential.
Is the price cut limited to one drug?
No — all nine companies committed to MFN pricing for every future drug they launch in the U.S.
This means → BeiGene's pricing power on its entire pipeline has been locked under a long-term cap from the moment of signing.
In plain terms = this is not a one-off concession. Every new drug BeiGene brings to the U.S. already has a price ceiling drawn above it.
How big is the financial hit?
Citi analyst Nathaniel and colleagues said the event has very limited impact on BeiGene's total revenue.
Key numbers: Tevimbra posted RMB 2.984 billion in global sales in H1 2026, up 12.9% year-on-year. By contrast, BeiGene's other flagship zanubrutinib (brand name: Brukinsa) generated RMB 11.39 billion in the U.S. alone over the same period — nearly 4× Tevimbra's global figure.
This reflects a revenue center of gravity firmly on zanubrutinib, not Tevimbra. A Tevimbra price cut barely moves the overall needle.
Can "volume for price" actually work?
Healthcare investor Wang Pengyu told the National Business Daily: "Trading price for volume faces enormous pressure — you need a massive jump in volume just to offset the price loss."
BeiGene's own framing: the deal supports the company's long-term development in the U.S. market and improves drug accessibility.
In plain terms = BeiGene is betting on "get more American patients on the drug now, recoup through scale later." Whether volume can compensate for price remains an open question.
Why did BeiGene volunteer for this?
A senior healthcare investor explained: the PD-1 space — a class of cancer drugs that activate the immune system to attack tumors — is fiercely competitive. Joining Medicaid could boost sales volume.
The U.S. accounts for more than half of BeiGene's product revenue. Cooperating with local stakeholders and broadening drug access fits its long-term strategy.
The same investor noted that the MFN mechanism benefits the U.S. market at the expense of other developed-country markets, so its real impact on BeiGene is relatively contained.
Can other Chinese drugmakers follow the same path?
The investor stressed that most Chinese innovative pharma companies have not yet completed U.S. commercialization and lack flagship products selling at scale in the country.
Many rely on out-licensing models and do not negotiate pricing directly with the U.S. government — making it hard to replicate BeiGene's route.
This means → BeiGene's deal is a one-off case, not an industry trend signal. The vast majority of Chinese drugmakers are simply not at that stage yet.
市场有风险，内容仅供研究参考，不构成投资建议。